Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial.

Lancet Gastroenterol Hepatol · 2018 · PMC6944204 · PMID 29242014

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendP = 0·07so close (0.05 < p ≤ 0.1)

Furthermore, the highest of the specific IgE values at baseline to any of the foods in the participants’ OIT showed a trend to be important for the study outcome in the placebo arm (P = 0·07, FDR adjusted P = 0·19, appendix p 7), while this was not the case in the omalizumab arm.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.